27
Jan
2022

Simcha, Backed by SR One, Raises $40m to Inject New Life Into IL-18 for Cancer

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Simcha Therapeutics Locks in $25 Million in Series A; Renews Interest in IL-18